Gilead ties up with 5 generic drugmakers in India, Pakistan for COVID-19 drug supply; licensees to set price for product

Gilead’s antiviral drug remdesivir earlier this month received the US Food and Drug Administration’s emergency use authorization to treat COVID-19 patients.

Reuters May 13, 2020 06:29:53 IST
Gilead ties up with 5 generic drugmakers in India, Pakistan for COVID-19 drug supply; licensees to set price for product

Gilead Sciences Inc said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.

The pacts allow the companies - Jubilant Life Sciences Ltd, Cipla Ltd, Hetero Labs Ltd, Mylan NV and Ferozsons Laboratories Ltd-to make and sell the drug in 127 countries.

The countries consist of nearly all low-income and lower-middle income ones, as well as several that are upper-middle- and high-income, the drugmaker said. Afghanistan, India, North Korea, Pakistan and South Africa are among the countries.

The licensees will also set their own prices for the generic product they produce, Gilead said.

Gilead ties up with 5 generic drugmakers in India Pakistan for COVID19 drug supply licensees to set price for product

Representational image. Image by Willfried Wende from Pixabay.

The licenses are royalty-free until the World Health Organization declares the end of the public health emergency regarding COVID-19, or until a product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, the company said.

Gilead’s antiviral drug remdesivir earlier this month received the US Food and Drug Administration’s emergency use authorization to treat COVID-19 patients.

With no other approved treatment for COVID-19, the respiratory illness caused by the novel coronavirus, interest in remdesivir has been growing, and the company is being closely watched on the pricing and distribution of the limited supply of the drug.

Gilead last week said it was negotiating long-term licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing countries and that it would provide technology to aid the production.

The pandemic has killed nearly 286,000 people globally, according to a Reuters tally, and several drugmakers are racing to develop a viable treatment or vaccine to combat the outbreak.

Updated Date:

also read

China to fully resume travel with Hong Kong, Macau from 6 February
World

China to fully resume travel with Hong Kong, Macau from 6 February

Even after China reopened its borders to the world on 8 January, a quota system and COVID testing requirement remained for travellers between the mainland and Hong Kong

Beijing has hit ‘temporary herd immunity’, says Chinese health official
World

Beijing has hit ‘temporary herd immunity’, says Chinese health official

A torrent of cases cascaded through China since the Communist Party abruptly ended its zero-Covid policy last month. But there have been signs that the surge has started to tail off, with authorities saying last week that the number of daily Covid-19 deaths had fallen by nearly 80 percent in January

North Korea lifts stringent epidemic lockdown in capital Pyongyang, says Russian embassy
World

North Korea lifts stringent epidemic lockdown in capital Pyongyang, says Russian embassy

North Korea has not officially acknowledged a lockdown in Pyongyang or a re-emergence of COVID-19 after leader Kim Jong Un declared a widely disputed victory over the coronavirus in August